Intracoronary brachytherapy - Clinical state and pathophysiological considerations

Current Pharmaceutical Design

Volumn 11, Issue 4, 2005, Pages 421-433

  Krötz, Florian ^a   Sohn, Hae Young ^b   Klauss, Volker ^b   Schiele, Thomas M ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Coronary angioplasty; Coronary stents; Edge effect; In stent restenosis; Intravascular irradiation; Late thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; IRIDIUM 192; PHOSPHORUS 32; PLACEBO; PYRIDINE DERIVATIVE; STRONTIUM 90; TICLOPIDINE; YTTRIUM 90;

ANGIOGRAPHY; ARTERY INTIMA PROLIFERATION; BAROTRAUMA; BLOOD VESSEL INJURY; BRACHYTHERAPY; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CATHETERIZATION; CLINICAL OBSERVATION; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DIABETES MELLITUS; ELECTRON THERAPY; GAMMA IRRADIATION; HUMAN; IN-STENT RESTENOSIS; IONIZING RADIATION; MEDICAL DECISION MAKING; NONHUMAN; PATHOPHYSIOLOGY; PHENOMENOLOGY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SAPHENOUS VEIN GRAFT; SURGICAL TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING; VEIN BYPASS;

BRACHYTHERAPY; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STENTS;

EID: 13444309654     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382025     Document Type: Review

References (140)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-495.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
3. Califf RM. Restenosis: the cost to society. Am Heart J 1995; 130: 680-684.
4. Hamon M, Bauters C, McFadden EP, Wernert N, Lablanche JM, Dupuis B, et al. Restenosis after coronary angioplasty. Eur Heart J 1995; 16 Suppl I: 33-48.
5. Waksman R, Bhargava B, White L, Chan RC, Mehran R, Lansky AJ, et al. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 2000; 101: 1895-1898.
6. Gruberg L, Waksman R. Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries. Expert Opin Investig Drugs 2001; 10: 891-907.
7. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250-256.
8. Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med 2001; 344: 243-249.
9. Waksman R, Weinberger J. Coronary brachytherapy in the drug-eluting stent era: don't bury it alive. Circulation 2003; 108: 386-388.
10. Teirstein PS, King S. Vascular radiation in a drug-eluting stent world: it's not over till it's over. Circulation 2003; 108: 384-385.
11. Williams DO. Intracoronary brachytherapy: past, present, and future. Circulation 2002; 105: 2699-2700.
12. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003; 107: 2274-2279.
13. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation 2003; 107: 2383-2389.
14. Reynolds MR, Rinaldi MJ, Pinto DS, Cohen DJ. Current clinical characteristics and economic impact of subacute stent thrombosis. J Invasive Cardiol 2002; 14: 364-368.
15. Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003; 41: 79S-88S.
16. Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, et al. Disease-Specific Health Status After Stent-Assisted Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery. One-Year Results From the Stent or Surgery Trial. Circulation 2003.
17. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002; 360: 965-970.
18. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124.
19. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687.
20. Mintz GS, Kent KM, Pichard AD, Satler LF, Popma JJ, Leon MB. Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. Circulation 1997; 95: 1791-1798.
21. Mintz GS, Kent KM, Pichard AD, Popma JJ, Satler LF, Leon MB. Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. Cardiol Clin 1997; 15: 17-29.
22. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94: 35-43.
23. Kent KM. Restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 61: 67G-70G.
24. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
25. Holmes DR, Jr. In-stent restenosis. Rev Cardiovasc Med 2001; 2: 115-119.
26. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med 2002; 3 Suppl 5: S4-S9.
27. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-1293.
28. Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 2000; 81: 63-88.
29. Phillips-Hughes J, Kandarpa K. Restenosis: pathophysiology and preventive strategies. J Vasc Interv Radiol 1996; 7: 321-333.
30. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987; 75: 636-642.
31. Waller BF, Pinkerton CA, Orr CM, Slack JD, VanTassel JW, Peters T. Morphological observations late (greater than 30 days) after clinically successful coronary balloon angioplasty. Circulation 1991; 83: I28-I41.
32. Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol 2000; 89: 160-167.
33. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996; 47: 315-331.
34. Fukao H, Matsuo O. Antithrombotic regulation in human endothelial cells by fibrinolytic factors. Semin Thromb Hemost 2000; 26: 33-38.
35. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68: 106-113.
36. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996; 28: 1643-1651.
37. Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555-562.
38. Viswanathan M, Stromberg C, Seltzer A, Saavedra JM. Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta. J Clin Invest 1992; 90: 1707-1712.
39. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, Tamura K, et al. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2000; 2: 13-20.
40. Azuma H, Hamasaki H, Sato J, Isotani E, Obayashi S, Matsubara O. Different localization of ETA and ETB receptors in the hyperplastic vascular wall. J Cardiovasc Pharmacol 1995; 25: 802-809.
41. Douglas SA, Ohlstein EH. Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. J Cardiovasc Pharmacol 1993; 22 Suppl 8: S371-S373.
42. Rosenberg RD. Vascular smooth muscle cell proliferation: basic investigations and new therapeutic approaches. Thromb Haemost 1993; 70: 10-16.
43. Lawrence R, Hartmann DJ, Sonenshein GE. Transforming growth factor beta 1 stimulates type V collagen expression in bovine vascular smooth muscle cells. J Biol Chem 1994; 269: 9603-9609.
44. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-1918.
45. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 96: 2280-2286.
46. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-98.
47. Ishida T, Tanaka K. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis 1982; 44: 161-174.
48. Matsuno H, Kozawa O, Niwa M, Uematsu T. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation 1997; 96: 1299-1304.
49. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992; 70: 593-599.
50. Condado JA, Waksman R, Gurdiel O, Espinosa R, Gonzalez J, Burger B, et al. Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation 1997; 96: 727-732.
51. Verin V, Urban P, Popowski Y, Schwager M, Nouet P, Dorsaz PA, et al. Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study. Circulation 1997; 95: 1138-1144.
52. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl Med 1997; 336: 1697-1703.
53. Teirstein PS, Massullo V, Jani S, Popma JJ, Russo RJ, Schatz RA, et al. Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000; 101: 360-365.
54. Waksman R, White RL, Chan RC, Bass BG, Geirlach L, Mintz GS, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000; 101: 2165-2171.
55. Mintz GS, Weissman NJ, Teirstein PS, Ellis SG, Waksman R, Russo RJ, et al. Effect of intracoronary gamma-radiation therapy on in-stent restenosis: An intravascular ultrasound analysis from the gamma-1 study. Circulation 2000; 102: 2915-2918.
56. Prpic R, Teirstein PS, Reilly JP, Moses JW, Tripuraneni P, Lansky AJ, et al. Long-term outcome of patients treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis. Circulation 2002; 106: 2340-2345.
57. Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 2002; 106: 1090-1096.
58. Suntharalingam M, Laskey W, Lansky AJ, Waksman R, White L, Teirstien P, et al. Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry. Int J Radiat Oncol Biol Phys 2002; 52: 1075-1082.
59. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 2002; 359: 551-557.
60. King SB III, Williams DO, Chougule P, Klein JL, Waksman R, Hilstead R, et al. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results of the beta energy restenosis trial (BERT). Circulation 1998; 97: 2025-2030.
61. Sabate M, Serruys PW, van der Giessen WJ, Ligthart JM, Coen VL, Kay IP, et al. Geometric vascular remodeling after balloon angioplasty and beta-radiation therapy: A three-dimensional intravascular ultrasound study. Circulation 1999; 100: 1182-1188.
62. Serruys PW, Kay IP. I like the candy, I hate the wrapper: the (32)P radioactive stent. Circulation 2000; 101: 3-7.
63. Kozuma K, Costa MA, Sabate M, Kay IP, Marijnissen JP, Coen VL, et al. Three-dimensional intravascular ultrasound assessment of noninjured edges of beta-irradiated coronary segments. Circulation 2000; 102: 1484-1489.
64. Der Giessen WJ, Regar E, Harteveld MS, Coen VL, Bhagwandien R, Au A, et al. "Edge Effect" of (32)p radioactive stents is caused by the combination of chronic stent injury and radioactive dose falloff. Circulation 2001; 104: 2236-2241.
65. Raizner AE, Oesterle SN, Waksman R, Serruys PW, Colombo A, Lim YL, et al. Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000; 102: 951-958.
66. Results of the BETA-CATH system trial. Late Breaking Clinical Trials, annual scientific session, American College of Cardiology. 2001.
67. Sianos G, Kay IP, Costa MA, Regar E, Kozuma K, de Feyter PJ, et al. Geographical miss during catheter-based intracoronary beta-radiation: incidence and implications in the BRIE study. Beta-Radiation In Europe. J Am Coll Cardiol 2001; 38: 415-420.
68. Krotz F, Schiele TM, Zahler S, Konig A, Rieber J, Kantlehner R, et al. Sustained platelet activation following intracoronary beta irradiation. Am J Cardiol 2002; 90: 1381-1384.
69. Schiele TM, Konig A, Zimmermann A, Krotz F, Sohn HY, Rieber J, et al. Safety and mechanisms of intracoronary manual stepping brachytherapy as gained from serial angiographic and intravascular ultrasound studies. Am J Cardiol 2002; 90: 1385-1388.
70. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Combination antiplatelet therapy following brachytherapy with restenting: it ain't over 'til the fat lady sings. J Invasive Cardiol 2002; 14: 115-117.
71. Teirstein P, Reilly JP. Late stent thrombosis in brachytherapy: the role of long-term antiplatelet therapy. J Invasive Cardiol 2002; 14: 109-114.
72. Waksman R, Cheneau E, Ajani AE, White RL, Pinnow E, Torguson R, et al. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. Circulation 2003; 107: 1744-1749.
73. Crocker I, Joyal M, Fox T, Arsenault A, Bonan R. Treatment of long, diffuse, in-stent restenotic lesions with beta radiation using strontium 90 and sequential positioning "pullback" technique: procedural details and clinical outcomes. J Invasive Cardiol 2001; 13: 782-787.
74. Costa R, Joyal M, Harel F, Fox T, Crocker I, Arsenault A, et al. Treatment of bifurcation in-stent restenotic lesions with beta radiation using strontium 90 and sequential positioning pullback technique: procedural details and clinical outcomes. J Invasive Cardiol 2003; 15: 469-473.
75. Ahmed JM, Mintz GS, Waksman R, Weissman NJ, Leiboff B, Pichard AD, et al. Serial Intravascular Ultrasound Analysis of the Impact of Lesion Length on the Efficacy of Intracoronary gamma-Irradiation for Preventing Recurrent In-Stent Restenosis. Circulation 2001; 103: 188-191.
76. Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21: 1739-1749.
77. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428-1436.
78. Mehilli J, Kastrati A, Dirschinger J, Dotzer F, Pache J, Hausleiter J, et al. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. Am J Med 2002; 112: 13-18.
79. O'Keefe JH, Blackstone EH, Sergeant P, McCallister BD. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J 1998; 19: 1696-1703.
80. Moses JW, Moussa I, Leon MB, Teirstein PS, Fish RD, Ellis SG, et al. Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial). Am J Cardiol 2002; 90: 243-247.
81. Gruberg L, Waksman R, Ajani AE, Kim HS, White RL, Pinnow EE, et al. The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus. J Am Coll Cardiol 2002; 39: 1930-1936.
82. Urban P, Serruys P, Baumgart D, Colombo A, Silber S, Eeckhout E, et al. A multicentre European registry of intraluminal coronary beta brachytherapy. Eur Heart J 2003; 24: 604-612.
83. Waksman R, Ajani AE, White RL, Chan RC, Satler LF, Kent KM, et al. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med 2002; 346: 1194-1199.
84. Ajani AE, Waksman R, Cheneau E, Cha DH, Leborgne L, Sharma AK, et al. Comparison of intracoronary gamma radiation for in-stent restenosis in saphenous vein grafts versus native coronary arteries. Am J Cardiol 2003; 91: 22-26.
85. Stone GW, Mehran R, Midei M, Waksman R, Schaer GL, Negoita M, et al. Usefulness of beta radiation for de novo and in-stent restenotic lesions in saphenous vein grafts. Am J Cardiol 2003; 92: 312-314.
86. Schiele TM, Regar E, Silber S, Eeckhout E, Baumgart D, Wijns W, et al. Clinical and angiographic acute and follow up results of intracoronary beta brachytherapy in saphenous vein bypass grafts: a subgroup analysis of the multicentre European registry of intraluminal coronary beta brachytherapy (RENO). Heart 2003; 89: 640-644.
87. Bass TA, Gilmore P, Zenni M, Sasseen B, Savage M, Bonan R, et al. Debulking does not benefit patients undergoing intracoronary beta-radiation therapy for in-stent restenosis: insights from the START trial. Catheter Cardiovasc Interv 2003; 58: 331-335.
88. Brenner DJ, Miller RC, Hall EJ. The radiobiology of intravascular irradiation. Int J Radiat Oncol Biol Phys 1996; 36: 805-810.
89. Wiedermann JG, Marboe C, Amols H, Schwartz A, Weinberger J. Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: persistent benefit at 6-month follow-up. J Am Coll Cardiol 1995; 25: 1451-1456.
90. Baumgart D, Sauerwein W, Naber C, Meusers P, Quast U, Eggebrecht H, et al. Dose finding in intracoronary brachytherapy - consequences from empirical trials. Z Kardiol 2002; 91 Suppl 3: 23-30.
91. Carlier SG, Marijnissen JP, Coen VL, van der Giessen WJ, Sabate M, Ligthart J, et al. Guidance of intracoronary radiation therapy based on dose-volume histograms derived from quantitative intravascular ultrasound. IEEE Trans Med Imaging 1998; 17: 772-778.
92. Sabate M, Costa MA, Kozuma K, Kay IP, van der Wiel CJ, Verin V, et al. Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy. Dose Finding Study Group. J Am Coll Cardiol 2000; 36: 1536-1541.
93. Kim HS, Waksman R, Chan RC, Pappas CK, Bhargava B, Ajani AE, et al. Safety and efficacy of manual stepping and overlapping of beta-emitter for diffuse in-stent restenosis lesions. Cardiovasc Radiat Med 2002; 3: 56-59.
94. Hall EJ, Miller RC, Brenner DJ. Radiobiological principles in intravascular irradiation. Cardiovasc Radiat Med 1999; 1: 42-47.
95. Fischer-Dzoga K, Dimitrievich GS, Schaffner T. Effect of hyperlipidemic serum and irradiation on wound healing in primary quiescent cultures of vascular cells. Exp Mol Pathol 1990; 52: 1-12.
96. Waksman R, Rodriguez JC, Robinson KA, Cipolla GD, Crocker IR, Scott NA, et al. Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Circulation 1997; 96: 1944-1952.
97. Kotzerke J, Gertler R, Buchmann I, Baur R, Hombach V, Norbert RS, et al. Different radiosensitivity of smooth muscle cells and endothelial cells in vitro as demonstrated by irradiation from a Re-188 filled balloon catheter. Atherosclerosis 2000; 152: 35-42.
98. Bertrand OF, Mongrain R, Thorin E, Lehnert S. In vitro response of human and porcine vascular cells exposed to high dose-rate gamma-irradiation. Int J Radiat Biol 2000; 76: 999-1007.
99. de Crom R, Wulf P, van Nimwegen H, Kutryk MJ, Visser P, van der KA, et al. Irradiated versus nonirradiated endothelial cells: effect on proliferation of vascular smooth muscle cells. J Vasc Interv Radiol 2001; 12: 855-861.
100. Shimotakahara S, Mayberg MR. Gamma irradiation inhibits neointimal hyperplasia in rats after arterial injury. Stroke 1994; 25: 424-428.
101. Mayberg MR, Luo Z, London S, Gajdusek C, Rasey JS. Radiation inhibition of intimal hyperplasia after arterial injury. Radiat Res 1995; 142: 212-220.
102. Rosen EM, Goldberg ID, Myrick KV, Levenson S. Radiation survival properties of cultured vascular smooth muscle cells. Radiat Res 1984; 100: 182-191.
103. Apisarnthanarax S, Chougule P. Intravascular brachytherapy: a review of the current vascular biology. Am J Clin Oncol 2003; 26: E13-E21.
104. Rubin P, Casarett GW. Clinical Radiation Pathology. Philadelphia. W.B. Saunders Co., 1986. 1986.
105. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Fineberg N, Hathaway DR. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 1995; 92: 2995-3005.
106. Cirillo P, Golino P, Ragni M, Battaglia C, Pacifico F, Formisano S, et al. Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovasc Res 1999; 43: 210-218.
107. Rubin P, Williams JP, Riggs PN, Bartos S, Sarac T, Pomerantz R, et al. Cellular and molecular mechanisms of radiation inhibition of restenosis. Part I: role of the macrophage and platelet-derived growth factor. Int J Radiat Oncol Biol Phys 1998; 40: 929-941.
108. Gaumond F, Fortin D, Stankova J, Rola-Pleszczynski M. Differential signaling pathways in platelet-activating factor-induced proliferation and interleukin-6 production by rat vascular smooth muscle cells. J Cardiovasc Pharmacol 1997; 30: 169-175.
109. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25 Suppl 2: S9-12.
110. Vodovotz Y, Waksman R, Kim WH, Bhargava B, Chan RC, Leon M. Effects of intracoronary radiation on thrombosis after balloon overstretch injury in the porcine model. Circulation 1999; 100: 2527-2533.
111. Salame MY, Verheye S, Mulkey SP, Chronos NA, King SB III, Crocker IR, et al. The effect of endovascular irradiation on platelet recruitment at sites of balloon angioplasty in pig coronary arteries. Circulation 2000; 101: 1087-1090.
112. Kaluza GL, Raizner AE, Mazur W, Schulz DG, Buergler JM, Fajardo LF, et al. Long-term effects of intracoronary beta-radiation in balloon- and stent-injured porcine coronary arteries. Circulation 2001; 103: 2108-2113.
113. Coussement PK, de Leon H, Ueno T, Salame MY, King SB III, Chronos NA, et al. Intracoronary beta-radiation exacerbates long-term neointima formation in balloon-injured pig coronary arteries. Circulation 2001; 104: 2459-2464.
114. Bostwick JS, Costanzo S, Byan L, Luo Y, Natarajan C, Bilder G. Clopidogrel but not ticlopidine produces an antiplatelet effect in the Yucatan minipig. Thromb Haemost 2000; 84: 928.
115. Cheneau E, John MC, Fournadjiev J, Chan RC, Kim HS, Leborgne L, et al. Time course of stent endothelialization after intravascular radiation therapy in rabbit iliac arteries. Circulation 2003; 107: 2153-2158.
116. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological Mechanisms of Fatal Late Coronary Stent Thrombosis in Humans. Circulation 2003. 108: 1701-6.
117. Neumann FJ, Off I, Gawaz M, Puchner G, Schomig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996; 27: 819-824.
118. Waksman R. Late thrombosis after radiation. Sitting on a time bomb. Circulation 1999; 100: 780-782.
119. Costa MA, Sabat M, van der Giessen WJ, Kay IP, Cervinka P, Ligthart JM, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999; 100: 789-792.
120. Waksman R, Bhargava B, Mintz GS, Mehran R, Lansky AJ, Satler LF, et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol 2000; 36: 65-68.
121. Waksman R, Ajani AE, White RL, Pinnow E, Dieble R, Bui AB, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001; 103: 2332-2335.
122. Waksman R, Ajani AE, Pinnow E, Cheneau E, Leborgne L, Dieble R, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002; 106: 776-778.
123. Kojima S, Matsumori S, Ono H, Yamaoka K. Elevation of glutathione in RAW 264.7 cells by low-dose gamma-ray irradiation and its responsibility for the appearance of radioresistance. Anticancer Res 1999; 19: 5271-5275.
124. Kojima S, Matsumori S, Ishida H, Yamaoka K. Possible role of elevation of glutathione in the acquisition of enhanced proliferation of mouse splenocytes exposed to small-dose gamma-rays. Int J Radiat Biol 2000; 76: 1641-1647.
125. Hyun SJ, Yoon MY, Kim TH, Kim JH. Enhancement of mitogen-stimulated proliferation of low dose radiation-adapted mouse splenocytes. Anticancer Res 1997; 17: 225-229.
126. Hanke H, Strohschneider T, Oberhoff M, Betz E, Karsch KR. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res 1990; 67: 651-659.
127. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369-375.
128. Hanke H, Kamenz J, Hassenstein S, Oberhoff M, Haase KK, Baumbach A, et al. Prolonged proliferative response of smooth muscle cells after experimental intravascular stenting. Eur Heart J 1995; 16: 785-793.
129. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105: 2974-2980.
130. Hehrlein C, DeVries JJ, Arab A, Haller SD, Schloesser K, Tio FO, et al. Failure of a novel balloon-expandable gamma-emitting ((103)Pd) stent to prevent edge effects. Circulation 2001; 104: 2358-2362.
131. Strauss BH, Li C, Whittingham HA, Tin FO, Kutryk MJ, Janicki C, et al. Late effects of low-energy gamma-emitting stents in a rabbit iliac artery model. Int J Radiat Oncol Biol Phys 2002; 54: 551-561.
132. Kuchulakanti P, Lew R, Waksman R. Mechanisms and methods to resolve edge effect. J Invasive Cardiol 2003; 15: 363-366.
133. Cheneau E, Wolfram R, Leborgne L, Waksman R. Understanding and preventing the edge effect. J Interv Cardiol 2003; 16: 1-7.
134. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, et al. Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. J Am Coll Cardiol 2002; 39: 274-280.
135. Albiero R, Nishida T, Adamian M, Amato A, Vaghetti M, Corvaja N, et al. Edge restenosis after implantation of high activity (32 P radioactive beta-emitting stents. Circulation 2000; 101: 2454-2457.
136. Albiero R, Adamian M, Kobayashi N, Amato A, Vaghetti M, Di Mario C, et al. Short- and intermediate-term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: The Milan Dose-Response Study. Circulation 2000; 101: 18-26.
137. Schiele TM, Staber L, Kantlehner R, Pollinger B, Duhmke E, Theisen K, et al. Edge effect and late thrombosis - inevitable complications of vascular brachytherapy?. Z Kardiol 2002; 91: 869-878.
138. Kipshidze N, Leon MB, Tsapenko M, Falotico R, Kopia GA, Moses J. Update on sirolimus drug-eluting stents. Curr Pharm Design 2004; 10(4): 337-48.
139. Mousa SA. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. Curr Pharm Design 2003; 9(28): 2317-22.
140. Windecker S, Roffi M, Meier B. Sirolimus eluting stent: a new era in interventional cardiology? Curr Pharm Design 2003; 9(13): 1077-94.